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GABAA receptors containing α2/3 subunits are current targets in the battle to develop new pain medications, as they are expressed
in the spinal cord where increasing inhibitory drive should result in analgesia. However, this approach is prone to a range of side
eﬀects including sedation, cognitive impairment, and abuse as a consequence of the widespread inﬂuence of GABA. The ability to
make subtype selective low-eﬃcacy benzodiazepine compounds, which potentiate the action of GABA at speciﬁc α subunits, has
thepotentialtoreducethissideeﬀectproﬁle.Inthisstudy,wehaveinvestigatedtheeﬀectsofthemedium-eﬃcacypositiveallosteric
modulator (PAM) L-838,417 and the low-eﬃcacy PAM TPA023 in a number of preclinical inﬂammatory and neuropathic pain
models. We conclude that either the higher level of eﬃcacy at α2/3 or eﬃcacy at α5 is required for compounds to have a signiﬁcant
analgesic eﬀect in a range of models, and, therefore, although the side-eﬀect proﬁle of compounds can be reduced compared to
typical benzodiazepines, it is unlikely that it can be completely eliminated.
1.Introduction
GABA and glycine are the main inhibitory neurotransmitters
in the CNS. GABA mediates its eﬀects through both
GABAA receptors which are ligand-gated ion-channels and
GABAB receptors which are GPCRs. GABAA receptors are
heteropentameric, and the majority of those present in the
CNS contain two α,t w oβ, and a single γ subunit [1].
Benzodiazepines are allosteric ligands, that is, they exhibit
no intrinsic activity of their own, but potentiate or inhibit
the eﬀects of GABA at receptors that contain either an α1,
2, 3, or 5 subunit [2]. GABA activation of GABAA receptors
leads to the opening of their integrated chloride channels.
Chloride inﬂux inhibits transmitter release from primary
aﬀerent terminals and hyperpolarizes spinal cord neurones,
decreasing the probability of ﬁring.
Inhibitory neurotransmission, in the spinal cord, is of
great importance in pain transmission, and enhancement
of inhibition leads to analgesia. Clinically, Ziconotide,
an N-type calcium channel blocker which inhibits neuro-
transmitter release in the spinal cord, was recently approved
for severe chronic pain [3]. However, its use is severely
limited by CNS side eﬀects, so there is a need for better
tolerated medications. It was only recently that GABAA
r e c e p t o r sa st a r g e t sf o rp a i nh a v eg a i n e ds o m es u p p o r tf r o m
preclinical evidence, with the use of both point mutant
diazepam insensitive GABAA mice and subtype selective
compounds. In particular, positive modulation of GABA
action at α2a n dα3 GABAA containing receptors, in the
spinal cord, results in pain relief [4]. This study looked at
a combination of diazepam eﬃcacy in point mutant mice
and the eﬃcacy of the α2/3/5 selective positive allosteric
modulator (PAM) L-838,417 [5] in a rat chronic constriction
injury (CCI) model to draw this conclusion. An additional
study has added weight to the evidence, as NS11394 (which
is also α2/3/5 selective [6]) is also analgesic in preclinical
models of inﬂammatory and neuropathic pain [7].2 Advances in Pharmacological Sciences
Compounds, such as TPA023 [8], which has no α1
activity, low levels of α2/3 eﬃcacy, and minimal activity at α5
subunits,havebeenshowntobeanxiolytic,bothpreclinically
and clinically [9]. However, so far all the preclinical pain
studies published have used compounds with higher eﬃcacy
than TPA023. Studies using cognitive enhancing α5s p e c i ﬁ c
NAMS suggest that PAM activity at α5 may be impair
cognition [10]; therefore, avoidance of this activity would
be an advantage in an analgesic. Furthermore, although α1
is likely the primary mediator of the addictive properties of
benzodiazepines [11], decreasing the level of α2/3 activity
may reduce the abuse potential of the compound [12]. We
were therefore interested in whether a compound showing a
lower level of α2/3 eﬃcacy and minimal activity at α1/5, with
little indication of acute clinical side eﬀects [13] would have
eﬃcacy in preclinical pain models. For that reason, in this
study, we have compared and contrasted the analgesic proﬁle
of L-838,417 (α12 % ,α2 43%, α3 43%, α5 39% compared to
chlordiazepoxide [5]) and TPA023 (α10 % ,α2 11%, α3 21%,
α5 5% compared to chlordiazepoxide [8]) in a wide range
of preclinical neuropathic and inﬂammatory pain models. In
addition, we have measured changes in qEEG beta frequency
as a potential biomarker of in vivo pharmacology. We ﬁnd
that the lower-eﬃcacy compound TPA023 does not exhibit
a broad analgesic proﬁle across the spectrum of preclinical
pain models and that this corresponds to nonsigniﬁcant
changes in the qEEG beta frequency. However, the higher-
eﬃcacy compound L-838,417 signiﬁcantly reverses allodynia
in the majority of the pain models tested and signiﬁcantly
increases qEEG beta frequency.
2.MaterialsandMethods
2.1. Animals. All experiments were conducted in accordance
with the United Kingdom (UK) Home Oﬃce Animals
(Scientiﬁc Procedures) Act (1986) and were subject to local
ethical review. Experiments were performed using male
Sprague Dawley rats in the light period of a twelve-hour
light/dark cycle. Animals were acclimatised to the facility for
at least ﬁve days prior to commencing studies, were group-
housed, unless otherwise stated, and had access to food and
water ad libitum. All surgical procedures were conducted in
aseptic conditions.
2.2. Receptor Occupancy (RO) Studies. RO was determined
using a separate cohort of animals, and these values corre-
lated to pharmacokinetic (PK) data obtained in the studies
described below. In RO studies, rats received either vehicle
control, L-838,417, or TPA023 (0.3, 1, or 10mg/kg) p.o.
Nonspeciﬁc binding was determined in a separate group
of animals by administering 5mg/kg bretazenil i.p.,w i t h
a thirty-minute pretreatment time. At three mins prior
to the cull, all rats were dosed i.v.w i t h1 0 μCi/kg [3H]
Ro 15-1788 (ﬂumazenil). Following euthanasia, the whole
brain was removed and homogenised in 10vol of ice-cold
buﬀer (10mM potassium phosphate/100mM potassium
chloride buﬀer, pH 7.4, 4◦C) using a polytron homogeniser
(setting 6 for 10s). Three 300μL aliquots of homogenate
were ﬁltered over 0.5% v/v polyethyleneimine-(PEI-) soaked
(Sigma, Poole, UK) GF/B ﬁlters (Whatman, Maidstone,
Kent) to separate the bound radioactivity from the free
radioactivity [14] and washed twice in 5mL ice-cold buﬀer.
Filters were then placed in vials, scintillation ﬂuid added
and radioactivity counted using a 3100TR TriCarb beta
liquid scintillation counter (Perkin-Elmer, Cambridge, UK).
Plasma samples were also collected for PK analysis. The
receptor occupancy values of L-838,417 and TPA023 were
determined by calculating the reduction in speciﬁc binding
in drug-treated rats relative to vehicle controls. Typically,
vehicle levels of radioactivity were around 2000dpm, and
non-speciﬁc (bretazenil treated) levels were around 50dpm.
2.3. Behavioural Studies. All behavioural studies were con-
ducted in a double-blind fashion. Animals were allocated to
treatment groups according to their baseline scores, in order
to balance groups. Plasma samples were taken in all studies
for PK analysis and to extrapolate brain RO levels.
2.4. Complete Freund’s Adjuvant-(CFA-) Induced Thermal
Hyperalgesia. Following training to the testing procedure,
rats (150–200g, Charles River, UK) received an intraplantar
injection of 100μg (in 100μL) CFA suspension (Sigma,
Poole, UK) to the right hind paw. Behavioural studies were
conductedtwentyfourhourslater.Followingacclimatisation
to the testing chamber, a mobile infrared heat source (Ugo
Basile, Italy) was applied directly below the plantar surface
of the contralateral hind paw (for a maximum of 20s) and
paw withdrawal latency time (PWL, s) measured, using a
modiﬁed method of Hargreaves et al. [15]. Three separate
readings were taken and an average value calculated. This
procedure was then repeated on the ipsilateral hind paw.
Animals were considered to be hyperalgesic if the ipsilateral
PWL value was 5s or less. Animals were then allocated to
treatment groups and received either vehicle, test compound
or 100mg/kg ibuprofen p.o. PWL was assessed again at one
hour postdose.
2.5. Tibial Nerve Transection-(TNT-) Induced Static Allo-
dynia. Tibial nerve transection was conducted using the
methods previously described by Lee et al. [16]. Rats (175–
200g,CharlesRiver,UK)wereanaesthetisedviaaninduction
chamber using 2% isoﬂurane (Abbott, Maidenhead, UK) in
oxygen. Once anaesthetised, animals were transferred to a
nose cone and a homeothermic blanket system for surgery
(Harvard Apparatus, Edenbridge, UK). The right common
sciatic nerve was exposed via blunt dissection through the
biceps femoris. The tibial nerve was tightly ligated using
two ligatures placed 3mm apart, 5mm distal to the sciatic
trifurcation. The tibial nerve was then cut and laid back in
its original position. The incision was closed, and animals
recovered in heated boxes before being returned to their
homecages. Two weeks postsurgery, animals were habituated
to test arenas and von Frey ﬁlaments (Stoelting, Wood
Dale, USA) over a three-day training period. Following this
training period, static allodynia was assessed using the up-
down method described by Chaplan et al. [17]. In brief,Advances in Pharmacological Sciences 3
von Frey ﬁlaments ranging from 0.4 to 15.0g were applied to
the plantar surface of the ipsilateral hind paw, starting with a
2.0gﬁlament.Filamentswerethenpresentedinanascending
or descending pattern, depending on the animal’s responses,
according to published methods. Each von Frey ﬁlament
was applied until a withdrawal response was obtained, up
to a maximum of six seconds. This was repeated on the
contralateral hind paw. Animals were considered to be
allodynic if the ipsilateral 50% paw withdrawal threshold
(50% PWT) value calculated using this paradigm was 4.0g
or less. Animals were then allocated to treatment groups and
received either vehicle, test compound or pregablin 20mg/kg
p.o. Static allodynia was assessed again at one hour postdose.
Studies were conducted four to eight weeks postsurgery.
2.6.ChronicConstrictionInjury-(CCI-)InducedStaticAllody-
nia. Rats (175–200g Charles River, UK) were anaesthetised
and the sciatic nerve exposed as described above. CCI
surgery was conducted as previously described by Bennett
and Xie [18]. In brief, proximal to the sciatic trifurcation,
approximately 7mm of nerve was freed from surrounding
tissue via blunt dissection and four loose ligations applied
(4–0 silk), each approximately 1mm apart. The incision
was closed, and animals recovered in heated boxes before
being returned to their homecages. Two weeks postsurgery,
animalswerehabituatedtotestarenasandvonFreyﬁlaments
as described above. Following this training period, static
allodynia was assessed using the up-down method described
above. Animals were considered to be allodynic if the
ipsilateral 50% PWT value was 4.0g or less. Animals were
then allocated to treatment groups and received either
vehicle, test compound, or pregablin 20mg/kg p.o. Static
allodynia was assessed again at one hour postdose. Studies
were conducted at two to four weeks postsurgery.
2.7. Spinal Nerve Ligation-(SNL-) Induced Static Allodynia
(Performed at Aptuit, Edinburgh, UK). Rats (200–300g,
Harlan, UK) were anaesthetised using isoﬂurane in oxygen.
The left L6 transverse process was removed and the L5
and L6 spinal nerves tightly ligated (6–0 silk) [19]. The
incision was closed, and animals recovered before being
returned to their homecages. Animals were acclimatised to
the testing procedure prior to SNL surgery and retested
twice after surgery as part of the training procedure.
Following this training period, static allodynia was assessed
two to three weeks postsurgery by applying a range of
von Frey ﬁlaments from 2.0 to 26.0g in ascending order.
Each ﬁlament was applied 8–10 times at a frequency of
1Hz. Both the contralateral and ipsilateral hind paws were
assessed. Animals were considered to be allodynic if the
ipsilateral paw withdrawal threshold (PWT) was 5.0g or
less. Animals were then allocated to treatment groups
and received either vehicle, test compound, or pregablin
50mg/kg p.o. Static allodynia was assessed again at one hour
postdose.
2.8. Electrophysiology Studies in CCI Animals. Following
CCI surgery and subsequent assessment of static allodynia,
ac o h o r to fa n i m a l sw e r eu s e df o rin vivo electrophysi-
ology studies (2.5–4.5 weeks postsurgery). Animals were
anaesthetised as described above. Surgery was conducted
under 2.5–3.5% isoﬂurane. The jugular vein and carotid
artery were cannulated and laminectomy performed in the
lumbarenlargementregion.Thespinalcordwasexposed,the
dura removed, and the cord covered in mineral oil (Sigma,
Poole, UK) at 37◦C throughout the remainder of the study.
Following surgery, isoﬂurane was decreased to 1.8–2.5% and
blood pressure monitored via the carotid artery cannula.
Extracellular, single-unit recordings were made using 5MΩ
ﬁne tungsten electrodes (A-M Systems Inc., Sequim, USA)
from wide dynamic range (WDR) neurones with a receptive
ﬁeld on the plantar surface of the ipsilateral hind paw.
Neuroneswerecharacterisedbyintensity-dependentﬁringto
a range of cutaneous stimuli. Action potentials were pream-
pliﬁed(NeurologNL100AKheadstage),ampliﬁed(Neurolog
NL104A), and ﬁltered (Neurolog NL125) (Digitimer, Wel-
wyn Garden City, UK), and recordings digitized using a
Power 1401 (CED, Cambridge, UK). Data were recorded
and analysed using Spike 2 (CED, Cambridge, UK). Once
identiﬁed, a noxious mechanical pinch stimulus was applied
to the centre of the cell’s receptive ﬁeld, via an 8cm Glover
bulldog clamp (503236, WPI, Stevenage, UK). This stimulus
was applied for ﬁve seconds at 10min intervals and evoked
responses recorded. The number of evoked potentials in 1–
5seconds of each stimulus application was calculated. Once
stability of response was achieved, stimuli were continued in
the presence of either L-838,417 or vehicle. Solutions were
infused via the jugular vein at 4mL/kg/hr over thirty mins.
Blood samples were taken from the carotid artery for PK
analysis. Studies were conducted in a randomised fashion.
2.9. Taqman Analysis of Tissue from TNT Animals. Fourteen
days after surgery (and following conﬁrmation of the
development of static allodynia), a cohort of TNT-injured
animals was used for analysis of KCC2 mRNA levels in
the dorsal horn of the ipsilateral spinal cord. Comparative
tissues were also taken from the contralateral side and
from a group of sham-operated animals. Tissues were lysed
using RLT buﬀer before extracting and purifying RNA using
an RNAeasy microkit (Qiagen, Crawley, UK). The RNA
quantity (A260) and purity (260/280 ratio) were assessed
using spectrophotometry, and the integrity was checked
using an Agilent 2100 Bioanalyser (Agilent, Winnersh, UK).
Following this, a two-step ampliﬁcation process was carried
out, before conducting Taqman analysis.
2.10. Electroencephalogram (EEG) Studies. Rats (250g,
Charles River, UK) were anaesthetised using isoﬂurane
anaesthesia as described above and implanted intraperi-
toneally with radio telemetric transmitters (TL11M2 F40-
EET, Data Sciences International, St. Paul, Minn, USA) and
withcorticalEEGelectrodes(stainlesssteelscrewelectrodes).
These were implanted epidurally over the left parietal
cortex (2.0mm anterior and 2.0mm lateral to lambda) and
over the left frontal cortex (2.0mm anterior and 2.0mm
lateral to bregma) for a frontal-parietal EEG recording [20].4 Advances in Pharmacological Sciences
Thec orticalelectr odesandac c ompan yingleadswer esecur ed
to the skull by covering with dental acrylic. Animals
recovered in heated boxes before being returned to their
homecages (from this point animals were single-housed).
EEG studies were conducted a minimum of two weeks after
surgery. At the beginning of the light phase, animals received
either L-838,417, TPA023, or vehicle control p.o. in a four-
way cross-over design, so that all animals received all of the
treatments, thus enabling within animal comparisons. EEG
datawerethenimmediatelyrecorded,samplingcontinuously
at 500Hz for four hours with Data Sciences International
hardware and Data Acquisition Gold version 3.01 software
(Data Sciences International, St. Paul, Minn, USA). Data
were analysed using Spike 6 (CED, Cambridge, UK). For the
EEG analysis, consecutive 12-s epochs were subjected to a
Fast Fourier Transform and the EEG power density within
four frequency bands (δ 1–4Hz; θ 6–9Hz; α 8–13Hz; β
13–40Hz; γ 40–80Hz) was calculated. Spectral analysis was
performed on raw data ﬁles, which were sampled as for
sleep data (512Hz, Hanning window). Epochs containing
artefacts were excluded from analysis, but otherwise, data
were integrated for each frequency band, as deﬁned above,
and mean values were computed for each.
2.11.QuantiﬁcationofthePlasmaConcentrationsofL-838,417
and TPA023. Quantiﬁcation of L-838,417 and TPA023 in
plasma was carried out using liquid chromatography-mass
spectrometry(LC-MS)overanumber ofoccasions.Atypical
system consisted of a binary pump (Agilent 1100 series),
autoinjector (CTC PAL), and API4000 triple quadrapole
mass spectrometer (Sciex). Typical HPLC conditions used
a Monolith C18 column with a binary solvent system
consisting of solvent mix (A) 0.027% v/v formic acid
and 10mM ammonium formate in 90:10 water:methanol
and solvent mix (B) 0.027% v/v formic acid and 10mM
ammonium formate in 90:10 methanol:water. The ﬂow
rate was 1200uL/min with the following gradient system: 0-
0.1min 0% B, increasing to 100% B at 0.45min and holding
until 2min, returning to 0% B at 2.1min and holding until
2.5min. Flow was diverted to waste for the ﬁrst min and
after 2.4min of each injection. The analytes were extracted
from a 50μL plasma sample following the addition of 10μL
of 1μg/mL internal standard solution (the two compounds
were used as internal standards for each other), 300μLo fp H
10boratebuﬀer,and1000μLofmethylt-butylether(MTBE)
before vortex mixing. Samples were then centrifuged at
13,000rpm for 15min at 4◦C, before transfer of 800μL
aliquots of the MTBE layer to a fresh 96-well plate which
were then evaporated to dryness under N2 at 40◦C. The
samples were then reconstituted with 100μL of the mobile
phase B, and up to 45μLi n j e c t i o n sw e r em a d eo nt ot h e
LC-MS system described. The compounds were monitored
using selective reaction monitoring with Q1/Q3 transitions
of 400.0/96.0 and 396.0/110.0 for L-838,417 and TPA023,
respectively. The retention times of L-838,417 and TPA023
were 1.8 and 1.9min, respectively. The concentration range
of the standard curves was typically 0.5–1000ng/mL and
linear regression equations of the standard curve required
correlation coeﬃcient of >0.97 for acceptance.
2.12.Drugs. ForRO,behaviouralandEEGstudiesL-838,417
(L-838) and TPA023 (Pﬁzer, Sandwich, UK) and pregablin
(Parke-Davis, Cambridge, UK) were formulated as a suspen-
sion in 0.5% methyl cellulose (Sigma, Poole, UK) vehicle.
Ibuprofen (Sigma, Poole, UK) was dissolved in saline. For
electrophysiology studies, L-838,417 was formulated as a
solution in 18% glycerol formal (Sigma, Poole, UK), 17%
solutol HS (BASF, Germany) and 65% saline vehicle. For
RO studies, bretazenil was formulated as a solution in 70%
polyethylene glycol (PEG) 300 (Sigma, Poole, UK), 30%
saline vehicle.
2.13. Statistical Analysis. Data are expressed as means ± sem,
unless stated. Statistical analysis of behavioural data and
KCC2mRNAlevelswasconductedusingaOne-WayAnalysis
of Variance test, with the exception of SNL data where
a nonparametric Mann-Whitney test was used. Statistical
analysis of electrophysiology data was conducted using a
two-sided t-test. EEG data were analysed using a Restricted
Maximum Likelihood (REML) analysis, followed by Fisher’s
post hoc analysis. In each case, treatment groups were
compared to time-matched vehicle control groups.
3. Results
The aim of this study was to determine whether GABAA
α2/3 selective, positive allosteric modulators with varying
eﬃcacies in vitro would aﬀect changes in in vivo, in preclin-
ical pain models. In order to fully interpret and compare
the data generated with the two compounds used, we ﬁrst
determined the brain GABAA receptor occupancy of both
L-838,417 and TPA023 and correlated this to nonprotein
bound plasma drug levels (Figure 1). In terms of Occ50
values, TPA023 was approximately 0.3mg/kg and L-838,417
was approximately 1mg/kg, these data are very similar to
those published by Merck [21, 22]. However, as equivalent
dosesdidnotalwaysresultinequivalentplasmaexposures,in
subsequent studies plasma samples were always taken for PK
analysis and drug levels correlated to brain GABAA receptor
RO values determined from the results described above.
In terms of eﬀects in preclinical pain models, we ﬁrst
examined the eﬀects of these two modulators in a CFA-
induced model of inﬂammatory pain. In this model, L-
838,417 signiﬁcantly increased PWL at 1mg/kg (7.8 ± 1.2s,
P<0.01) and 10mg/kg (8.5 ± 0.6s, P<0.01), but
was not eﬃcacious at 0.3mg/kg p.o., when compared to
vehicle control (4.9 ± 0.4s)(Figure 2(a)). Free plasma drug
levels at these doses corresponded to 64, 90 and 44% brain
GABAA RO,respectively.Thesedatasuggestedalinkbetween
brain RO and in vivo eﬃcacy in this inﬂammatory pain
model. In the same model, no statistically signiﬁcant eﬀect
w a so b s e r v e dw i t hT P A 0 2 3a td o s e su pt o1 0 m g / k gp.o.
(Figure 2(b)), corresponding to 98% brain RO. Therefore,
it appeared that in vitro eﬃcacy, in addition to in vivo RO,Advances in Pharmacological Sciences 5
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Figure 1: GABAA receptor occupancy of (a) L-838,417 and (b)
TPA023 in whole rat brain compared to drug concentrations in the
plasma (nM free). Each datapoint represents an individual animal.
was an important factor in determining the in vivo eﬃcacy
of GABAA modulators in pain models.
These compounds were then assessed in a model of neu-
ropathicpain.Surprisingly,incontrasttotheresultsobtained
in the above inﬂammatory model, no signiﬁcant eﬀect was
observed with either compound in the TNT neuropathic
model of static allodynia (Figure 3), where the top doses cor-
respond to 97% RO for TPA023 and 100% RO for L-838,417.
This was also in contrast to data previously published by
other authors in the CCI model of neuropathic pain [4].
In order to further investigate this discrepancy between
our data and that reported by others, both compounds were
then tested in a CCI model. L-838,417 signiﬁcantly increased
50% PWT in this model at 10mg/kg p.o. (9.0 ± 1.2s,P<
0.05) compared to vehicle (3.6 ± 0.9s) (Figure 4(a)). This
dose corresponded to 94% RO. A trend for an increase in
50% PWT was also observed at 30mg/kg p.o. Although this
eﬀect was not statistically signiﬁcant, this value was not
signiﬁcantly diﬀe r e n tf r o mt h a to b t a i n e da t1 0m g / k g( P =
0.074). TPA023 also signiﬁcantly increased 50% PWT in CCI
animals at 1mg/kg p.o. (9.1 ± 1.8s,P<0.05) with respect
to vehicle control (3.6 ± 0.7s), but this was not observed at
anyotherdose(Figure 4(b)).Thisdosecorrespondedto98%
RO.
These apparent diﬀerences in the eﬀects of GABAA
allosteric modulators in models of neuropathic pain were
studiedfurtherbytestingbothcompoundsinanSNLmodel.
L-838,417 signiﬁcantly increased PWT in SNL animals at
10 and 30mg/kg p.o. (14.4 ± 2.6g and 12.9 ± 3.1g, resp.,
P<0.05 relative to vehicle control 4.1 ± 2.3g)(Figure 5(a)).
These doses corresponded to 60 and 100% RO, respectively.
TPA023 was also eﬃcacious in this model of static allodynia
at 10mg/kg p.o. (9.9 ± 1.8g,P<0.05) versus vehicle control
(4.9 ± 2.4g)(Figure 5(b)). This dose corresponded to 100%
RO. These results suggested that when a compound with
lower in vitro eﬃcacy is able to exert an eﬀect in in vivo pain
models, it may be necessary to achieve higher brain RO levels
than with a higher eﬃcacy compound.
Following initial behavioural assessment, L-838,417 was
also tested in CCI-injured animals in an in vivo electrophysi-
ology study. The aim of this study was to determine whether
GABAA receptormodulationwasaﬀectingspinalnerveﬁring
or reﬂex behaviours. Pinch-evoked ﬁring of WDR neurones
in CCI-injured animals was signiﬁcantly decreased thirty
mins after beginning i.v. administration of L-838,417 (58.0±
8.4% preinfusion number of action potentials, P<0.05),
relative to vehicle control (88.0 ± 7.1% preinfusion number
of action potentials) (Figure 6). Drug levels at this timepoint
corresponded to 86% RO. Due to the considerable number
of animals utilised in these studies, we did not test TPA023
due to the weaker eﬀect seen in the CCI behavioural study.
Other groups have reported that GABA activity can be
excitatory in certain conditions due to decreased levels of
the potassium chloride cotransporter KCC2 [23]. In our
studies, the only experimental model in which no eﬃcacy
was observed with either GABAA modulator was the TNT
model of neuropathic pain. We therefore examined KCC2
mRNA levels in this model using Taqman analysis. We found
nosigniﬁcantdiﬀerencesindorsalhornKCC2levelsinsham,
ipsilateral TNT, and contralateral TNT tissues (Figure 7). As
we observed a signiﬁcant eﬀect of GABAA PAMS in the CCI
and SNL model, we did not investigate any potential changes
in KCC2 levels in tissues from these models.
Finally,westudiedtheeﬀectsofL-838,417andTPA023in
a quantitative EEG model, to assess the functional activation
in a translatable pharmacology biomarker assay. L-838,417
dose-dependently increased the power in the beta frequency
relative to vehicle control over a four-hour period (Figure 8).
There appeared to be a trend towards an increase in this
value with TPA023, but this was not statistically signiﬁcant.
PK samples could not be taken during these studies for
technical reasons, so we were able to correlate these data
exactlywithRO.However,thethreedosesofeachcompound
weretargeting50,75and>100%RO,respectively,and,based
on experience, we are conﬁdent that we achieved 100% RO
at the highest dose.
4. Discussion
In this paper, we have investigated the level of α2/3/5
eﬃcacy required for GABAA PAMS to exhibit eﬃcacy in6 Advances in Pharmacological Sciences
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Figure 2: The eﬀects of (a) L-838,417 and (b) TPA023 on complete Freund’s adjuvant-induced thermal hyperalgesia in the rat. Data are
means ± sem. n = 7-8. Data are expressed as paw withdrawal latency (PWL). BL: baseline. (∗=P<0.05, ∗∗ = P<0.01, ANOVA
compared to vehicle-treated group).
preclinical pain models. We have shown that L-838,417,
whichexhibitsmoderateα2/3/5eﬃcacy,exhibitsasigniﬁcant
eﬀect in the majority (4/5) of preclinical pain models
in which it was tested. Conversely, a lower-eﬃcacy α2/3
compound,TPA023,withminimalα5activity,onlyexhibited
a signiﬁcant analgesic eﬀect in two out of the four preclinical
pain models investigated.
Furthermore, we have revealed that, even considering
that we reached ∼100% RO in all studies, the eﬀect of the
same compound across similar preclinical neuropathic pain
models diﬀers considerably. L-838,417 was able to reverse
the deﬁcit in paw withdrawal induced by either CCI or SNL,
but not TNT surgery, despite behavioural testing at similar
timepoints after surgery across the diﬀerent models. It has
been proposed that changes in chloride homeostasis, due
to decreases in expression of the potassium chloride co-
transporter KCC2, may cause GABA transmission to become
excitatory rather than inhibitory [23, 24]. This has led to
much debate, as to whether GABAA PAMS will be of utility
inthetreatmentofneuropathicpain.Duetothelackofeﬀect
of L-838,417 in our TNT model, we did investigate whether
there were any changes in KCC2 expression 14 days after
surgery (maximal allodynia), we found no changes in either
mRNA or protein expression (data not shown) in either the
ipsilateral or contralateral dorsal horn. It is possible that a
deﬁcit had normalised by this time point, as observed byAdvances in Pharmacological Sciences 7
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Figure 3: The eﬀects of (a) L-838,417 and (b) TPA023 on tibial nerve transection-induced static allodynia in the rat. Data are means ±sem.
n = 22. Data are expressed as 50% paw withdrawal threshold (PWT). BL: baseline. (∗∗ = P<0.01, ANOVA compared to vehicle-treated
group).
G. Miletic and V. Miletic [25], but in this case, any change
in chloride homeostasis should have also normalised, so
we conclude that a change in KCC2 expression was not
responsible for the lack of GABAA PAM eﬃcacy observed
in the TNT model. Additionally, in human clinical studies,
midazolam has been shown to have signiﬁcant analgesic
properties when given i.t in posthepatic neuralgia patients
[26], suggesting that in the clinical neuropathic population,
there is unlikely to be a reversal in chloride homeostasis.
We do not have a conclusive explanation for the diﬀerent
eﬀect of GABAA PAMS across the neuropathic models, as
diﬀerences between them are not well understood. The
C C Im o d e li sr e p o r t e dt ob em o r es e n s i t i v et om e c h a n i c a l
stimuli than the SNL model [27], but there has not been a
comprehensive study comparing which models respond best
to which pharmacological approaches. It could be the case
thatintheTNTmodel,thatthereisalackofinhibitorydrive,
and, therefore, there is no beneﬁt in enhancing it. Often
with comparing data between laboratories, it may be that
slight diﬀerences in surgery, time-point after surgery tested,
or even the genetic background of the animals used makes
more diﬀerence to outcome, than which model is used. In
our opinion, it is therefore diﬃcult to interpret results from
preclinical neuropathic models when assessing novel targets.8 Advances in Pharmacological Sciences
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Figure 4: The eﬀects of (a) L-838,417and (b) TPA023 on chronic constriction injury-induced static allodynia in the rat. Data are means ±
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Additionally, it is not believed that preclinical pain models
accurately represent human clinical pain [28], so their value
w h e nu s e da l o n ei sl i m i t e d .
As well as the above issues, in behavioural models, it can
be diﬃcult to separate out side eﬀects from a true analgesic
response. In particular, sedation can lead to a decrease in
paw-withdrawal latency in evoked endpoints in preclinical
models (internal data). Although data is always collected on
thecontralateralpawtotryandgatherglobalisedbehavioural
changes data and minimise any misinterpretation of the
ipislateral data, because of the diﬀerence in baseline between
the two paws, it is possible that there may still be some
side eﬀect interference. Indeed, reviewing the published data
on L-838,417, we consider that, although no statistics are
given, it appears that there is a deﬁcit in the dark phase of
the fear-potentiated startle test [5]. Furthermore, we have
also observed that zolpidem-trained rats generalise slightly
when given L-838,417 (data not shown). Both of these
observations suggest that L-838,417 may not completely
lack in vivo activity at the α1subunit. In addition, although
rotorod performance is less impaired by diazepam in the α1
KI mice, there is still a deﬁcit in performance at high doses
[5], pointing towards a motor-impairment eﬀect, possibly
muscle relaxation, mediated through one of the other α
subunits. Additionally, TPA023B which has a similar in vitro
proﬁle to L-838,417 reportedly causes eﬀects such as ﬂaccidAdvances in Pharmacological Sciences 9
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Figure 5: The eﬀects of (a) L-838,417 and (b) TPA023 on spinal nerve ligation-induced static allodynia in the rat. Data are means ± sem.
n = 10. Data are expressed as paw withdrawal threshold (PWT). BL: baseline. (∗=P<0.05, ∗∗ = P<0.01 compared to vehicle-treated
group. Mann-Whitney nonparametric test).
body tone in conscious animals [29]. We consider, however,
that the data obtained in the CCI-wide dynamic range
(WDR) study provide unequivocal evidence that GABAA
PAMS do signiﬁcantly aﬀect pain signalling. This is because
recordings are from individual spinal WDR neurones, which
respond to a range of sensory stimuli. Increasing intensities
of stimulation cause increasing cell ﬁring, with maximal
ﬁring caused by noxious stimuli. These cells signal pain
(intensity and location) to the brain. The CCI-WDR assay
is designed to measure the eﬀects of compounds on activity
evoked in WDR neurones by peripheral stimuli that are in
the noxious range, and L-838,417 was able to reduce the
amount of nerve ﬁring caused by a pinch stimulus in these
animals.
With regards to receptor occupancy (RO), even the
higher activity compound L-838,417 required at least 60%
RO in preclinical models to exhibit signiﬁcant eﬃcacy.
Indeed, the SNL model appeared to be the most sensitive of
the neuropathic models with regards detecting an analgesic
eﬀect, with L-838,417 requiring 60% RO and TPA023
requiring 100%, which correlates well with their diﬀerent in
vitro proﬁles. Conversely, in the CFA-thermal inﬂammatory
model although L-838,417 again had an analgesic eﬀect at
60%RO,TPA023wasineﬀectiveinthismodel.Howreceptor
occupancy requirements will translate from the preclinical
to clinical setting is diﬃcult to estimate. The optimistic
viewpointwouldbethatsimilartothesedativeandanxiolytic
properties of classical benzodiazepines, such as zolpidem10 Advances in Pharmacological Sciences
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Figure 7: KCC2 mRNA levels in the dorsal horn of the rat spinal
cord following either chronic constriction injury (CCI) or sham
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and lorazepam, that lower occupancy is required in the
clinical setting to achieve signiﬁcant eﬀects [30, 31], but
this hypothesis needs clinical data to support it. In phase 1
safety studies, TPA023 was shown to be well tolerated up
to approximately 60% receptor occupancy [9], in addition
TPA023B which has a similar in vitro proﬁle to L-838,417
was also well tolerated up to approximately 60% receptor
occupancy [32]. This was an acute study, however, and, at
higher doses, the reported side eﬀect proﬁle of TPA023B
appears to be worse than that of TPA023, with clear sedative
and ataxic eﬀects.
Overall, our data cannot diﬀerentiate whether it is the
higher α2/3 activity exhibited by L-838,417 compared to
TPA023 that leads to a more robust analgesic proﬁle in
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Figure 8: The eﬀects of (a) L-838,417 and (b) TPA023 on
quantitative electroencephalogram (EEG) in the telemetered rat.
Data are expressed as the total power in the beta frequency of the
EEG signal over a four-hour period, as a percentage of vehicle
control. Data are means ± sed. n = 6. Studies were four-period
crossovers, and therefore means and SED’s are adjusted for period
and rat eﬀects. ∗∗ = P<0.01 compared to vehicle-treated
group. Restricted maximum likelihood (REML) analysis, followed
by Fisher’s post hoc analysis.
preclinical pain models, or whether the diﬀerence is due to
the α5 activity present in L-838,417. Both of the functionally
selective GABAA compounds currently published in the
literature which exhibit a signiﬁcant eﬀect in preclinical
pain models do show reasonable activity at α5[ 4, 7]. In
addition, in knockin mice, the eﬃcacy of diazepam against
mechanical and heat allodynia was signiﬁcantly reduced in
the α5 KI’s after CCI surgery [4], suggesting that this subunit
doesplaysomeroleinmediatingtheanalgesiceﬀectsofthese
compounds.Hopefully,advancesinmedicinalchemistryand
the production of more selective compounds will allow this
question to be answered in the near future.Advances in Pharmacological Sciences 11
Finally, in order to have a translatable measure of α2
activityinvivo,wealsoinvestigatedthechangesinqEEGbeta
frequency produced by L-838,417 and TPA023. Preclinically,
the beta frequency is considered to be a marker of α2
activity, as qEEG studies have shown that the change in
diazepam-induced beta frequency remains unaﬀected in α1
or α3 knockin mice [33–35], but was reduced in mice with
diazpam-insensitive α2 subunits. In these mice, α2 subunits
were functional (i.e., they respond normally to GABA) but
are diazepam insensitive. Clinical qEEG changes have been
reported for a number of benzodiazepine compounds [36–
38], although the clinical data supporting a correlation
between beta frequency and α2 has not, at this time, been
generated. Our preclinical qEEG data correlate well with
the reported in vitro activity of the two compounds and to
some extent mimic the eﬀects observed in our preclinical
pain models, with L-838,417 exhibiting a signiﬁcant change
in beta frequency in a dose-related fashion, but TPA023
exhibiting a nonsigniﬁcant trend to increase. We propose
that changes in qEEG beta frequency may be an appropriate
pharmacological biomarker for α2 selective GABAA PAMS.
5. Conclusions
We conclude that GABAA functionally selective PAMSs are
likely to have broad utility in treating clinical pain. We
consider,however,itisunlikelythatalow-eﬃcacycompound
such as TPA023 will show suﬃcient eﬃcacy in the clinic.
The balance of an increasing side eﬀect proﬁle and eﬃcacy
will therefore have to be carefully considered when taking
compounds into clinical testing. We also recommend the use
of qEEG as an early marker of pharmacology in the clinical
setting.
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